Volume 11 Issue 4
Jul.  2020
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2020  >  11(4): 466-470
Sun Chao, Meng Xingchu, Dong Chong, et al. Clinical efficacy analysis of pediatric blood type incompatible living donor liver transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(4): 466-470. doi: 10.3969/j.issn.1674-7445.2020.04.007
Citation: Sun Chao, Meng Xingchu, Dong Chong, et al. Clinical efficacy analysis of pediatric blood type incompatible living donor liver transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(4): 466-470. doi: 10.3969/j.issn.1674-7445.2020.04.007
shu

Clinical efficacy analysis of pediatric blood type incompatible living donor liver transplantation

doi: 10.3969/j.issn.1674-7445.2020.04.007

  • Organ Transplantation Center, Tianjin First Central Hospital, Tianjin Key Laboratory of Organ Transplantation, Tianjin 300192, China

More Information
  • Corresponding author: Gao Wei, Email: gaowei_tjfch@163.com
  • Received Date: 2020-04-21
    Available Online: 2021-01-19
  • Publish Date: 2020-07-15
    Abstract
  •   Objective  To explore the clinical efficacy of pediatric blood type incompatible living donor liver transplantation.  Methods  The clinical data from 242 cases of pediatric living donor liver transplantation recipients were retrospectively analyzed. Recipients were assigned to group A (ABO-identical group, n=165), group B (ABO-compatible group, n=42) and group C (ABO-incompatible group, n=35) according to the blood type compatibility between the recipients and the donors. The occurrence of postoperative complications and development of postoperative donor specific antibody (DSA) among the 3 groups were observed and compared. And the blood type distribution of donors and recipients and development of erythrocyte antibodies in group C were analyzed. The survival situation of recipients after liver transplantation was compared among the 3 groups.  Results  There was no significant difference in the incidence of complications among the 3 groups(all P > 0.05). DSA was dominated by human leukocyte antigen (HLA) Ⅱ antibodies after liver transplantation, mostly anti-HLA-DR and anti-HLA-DQ. The postoperative erythrocyte antibodies for liver transplant recipients in group C were dominated by IgM, with titers ≤1:2 for all. The differences in postoperative survival rates were not statistically significant among 3 groups(all P > 0.05).  Conclusions  Pediatric blood type incompatible living donor liver transplantation is a safe and effective treatment, which can effectively expand the source of liver transplant donors and save the children's lives.

     

    • FullText(HTML)
  • loading
    • References(27)
  • [1]
    KELLY D, VERKADE HJ, RAJANAYAGAM J, et al. Late graft hepatitis and fibrosis in pediatric liver allograft recipients: current concepts and future developments[J]. Liver Transpl, 2016, 22(11):1593-1602. DOI: 10.1002/lt.24616.
    [2]
    MYSORE KR, HIMES RW, RANA A, et al. ABO-incompatible deceased donor pediatric liver transplantation: novel titer-based management protocol and outcomes[J]. Pediatr Transplant, 2018, 22(7):e13263. DOI: 10.1111/petr.13263.
    [3]
    DAHLGREN US, BENNET W. ABO-incompatible liver transplantation - a review of the historical background and results[J]. Int Rev Immunol, 2019, 38(3):118-128. DOI: 10.1080/08830185.2019.1601720.
    [4]
    HONDA M, SUGAWARA Y, KADOHISA M, et al. Long-term outcomes of ABO-incompatible pediatric living donor liver transplantation[J]. Transplantation, 2018, 102(10):1702-1709. DOI: 10.1097/TP.0000000000002197.
    [5]
    SUN C, SONG Z, MA N, et al. The management and outcomes of ABO-incompatible pediatric liver transplantation: experience of a single Chinese center[J]. J Pediatr Surg, 2020: S0022-3468(20)30151-2. DOI: 10.1016/j.jpedsurg.2020.01.059.
    [6]
    KASAHARA M, UMESHITA K, SAKAMOTO S, et al. Living donor liver transplantation for biliary atresia: an analysis of 2 085 cases in the registry of the Japanese Liver Transplantation Society[J]. Am J Transplant, 2018, 18(3):659-668. DOI: 10.1111/ajt.14489.
    [7]
    CHANG CH, BRYCE CL, SHNEIDER BL, et al. Accuracy of the pediatric end-stage liver disease score in estimating pretransplant mortality among pediatric liver transplant candidates[J]. JAMA Pediatr, 2018, 172(11):1070-1077. DOI: 10.1001/jamapediatrics.2018.2541.
    [8]
    RAWAL N, YAZIGI N. Pediatric liver transplantation[J]. Pediatr Clin North Am, 2017, 64(3):677-684. DOI: 10.1016/j.pcl.2017.02.003.
    [9]
    NG VL, MAZARIEGOS GV, KELLY B, et al. Barriers to ideal outcomes after pediatric liver transplantation[J]. Pediatr Transplant, 2019, 23(6):e13537. DOI: 10.1111/petr.13537.
    [10]
    TOKODAI K, KUMAGAI-BRAESCH M, KARADAGI A, et al. Blood group antigen expression in isolated human liver cells in preparation for implementing clinical ABO-incompatible hepatocyte transplantation[J]. J Clin Exp Hepatol, 2020, 10(2):106-113. DOI: 10.1016/j.jceh.2019.07.001.
    [11]
    MARKS WH, MAMODE N, MONTGOMERY RA, et al. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial[J]. Am J Transplant, 2019, 19(10):2876-2888. DOI: 10.1111/ajt.15364.
    [12]
    UMESHITA K, INOMATA Y, FURUKAWA H, et al. Liver transplantation in Japan: registry by the Japanese Liver Transplantation Society[J]. Hepatol Res, 2016, 46(12):1171-1186. DOI: 10.1111/hepr.12676.
    [13]
    KIVELÄ JM, KOSOLA S, PERÄSAARI J, et al. Donor-specific antibodies after pediatric liver transplantation: a cross-sectional study of 50 patients[J]. Transpl Int, 2016, 29(4):494-505. DOI: 10.1111/tri.12747.
    [14]
    TOKODAI K, MIYAGI S, NAKANISHI W, et al. Characteristics and predictive value for graft fibrosis of the complement-binding capacity of donor-specific human leukocyte antigen antibodies after pediatric liver transplantation[J]. Pediatr Transplant, 2020, 24(1):e13648. DOI: 10.1111/petr.13648.
    [15]
    TOKODAI K, MIYAGI S, NAKANISHI C, et al. Effect of recipient age at liver transplantation on prevalence of post-transplant donor-specific HLA antibody[J]. Ann Transplant, 2017, 22:333-337. doi: 10.12659/AOT.903926
    [16]
    KASAHARA M, KIUCHI T, TAKAKURA K, et al. Postoperative flow cytometry crossmatch in living donor liver transplantation: clinical significance of humoral immunity in acute rejection[J]. Transplantation, 1999, 67(4):568-575. doi: 10.1097/00007890-199902270-00014
    [17]
    SAVAGE TM, SHONTS BA, LAU S, et al. Deletion of donor-reactive T cell clones after human liver transplant[J]. Am J Transplant, 2020, 20(2):538-545. DOI: 10.1111/ajt.15592.
    [18]
    PERITO ER, MARTINEZ M, TURMELLE YP, et al. Posttransplant biopsy risk for stable long-term pediatric liver transplant recipients: 451 percutaneous biopsies from two multicenter immunosuppression withdrawal trials[J]. Am J Transplant, 2019, 19(5):1545-1551. DOI: 10.1111/ajt.15255.
    [19]
    NAKAMURA T, SHIROUZU T, NAKATA K, et al. The role of major histocompatibility complex in organ transplantation- donor specific anti-major histocompatibility complex antibodies analysis goes to the next stage[J]. Int J Mol Sci, 2019, 20(18):E4544. DOI: 10.3390/ijms20184544.
    [20]
    TOKODAI K, MIYAGI S, NAKANISHI C, et al. Association of post-transplant donor-specific HLA antibody with liver graft fibrosis during long-term follow-up after pediatric liver transplantation[J]. Pediatr Transplant, 2018, 22(3):e13169. DOI: 10.1111/petr.13169.
    [21]
    FENG S, BUCUVALAS JC, DEMETRIS AJ, et al. Evidence of chronic allograft injury in liver biopsies from long-term pediatric recipients of liver transplants[J]. Gastroenterology, 2018, 155(6):1838-1851. DOI: 10.1053/j.gastro.2018.08.023.
    [22]
    WOZNIAK LJ, NAINI BV, HICKEY MJ, et al. Acute antibody-mediated rejection in ABO-compatible pediatric liver transplant recipients: case series and review of the literature[J]. Pediatr Transplant, 2017, 21(1). DOI: 10.1111/petr.12791.
    [23]
    TOKODAI K, MIYAGI S, NAKANISHI C, et al. Impact of the trough level of calcineurin inhibitor on the prevalence of donor-specific human leukocyte antigen antibodies during long-term follow-up after pediatric liver transplantation: antibody strength and complement-binding ability[J]. Transplant Direct, 2017, 3(8):e196. DOI: 10.1097/TXD.0000000000000713.
    [24]
    孙超, 李姗霓, 马楠, 等.对小儿肝移植术后早期供体特异性抗体的监测观察[J/CD].实用器官移植电子杂志, 2018, 6(4):300-303. DOI: 10.3969/j.issn.2095-5332. 2018.04.010.

    SUN C, LI SN, MA N, et al. Observation of donor specific antibody in the early period post pediatric liver transplantation[J/CD]. Pract J Organ Transplant (Electr Vers), 2018, 6(4):300-303. DOI: 10.3969/j.issn.2095-5332. 2018.04.010.
    [25]
    ELISOFON SA, MAGEE JC, NG VL, et al. Society of pediatric liver transplantation: current registry status 2011-2018[J]. Pediatr Transplant, 2020, 24(1):e13605. DOI: 10.1111/petr.13605.
    [26]
    LEE EC, KIM SH, PARK SJ. Outcomes after liver transplantation in accordance with ABO compatibility: a systematic review and Meta-analysis[J].World J Gastroenterol, 2017, 23(35):6516-6533. DOI: 10.3748/wjg.v23.i35.6516.
    [27]
    邢爱丽, 郑加生.经肝动脉化疗栓塞术联合局部热消融治疗大肝癌的效果及影响因素[J].临床肝胆病杂志, 2019, 35(1):98-103.DOI:10.3969/j.issn.1001-5256. 2019.01.018.

    XING AL, ZHENG JS. Clinical effect of transcatheter arterial chemoembolization combined with local thermal ablation in treatment of large hepatocellular carcinoma and related influencing factors[J]. J Clin Hepatol, 2019, 35(1):98-103. DOI: 10.3969/j.issn.1001-5256.2019.01.018.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (178) PDF downloads(23) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return